INTRODUCTION
Multiple sclerosis (MS) is a complex autoimmune disorder of the central nervous system characterised by inflammatory demyelination on a background of progressive neurodegeneration. The aetiology of MS is still uncertain; 1 however, a complex interplay between genetic and environmental factors likely contributes to disease onset. Of the environmental risk factors linked to MS, the robust latitudinal gradients of prevalence 2 and incidence rate 3 have been among the most consistent and striking findings in MS epidemiology. 4 Indeed, we previously showed a positive association between latitude and MS prevalence with a 1.04 change in prevalence per degreelatitude (p<0.001), 2 while Alonso and Hernán 3 demonstrated that MS incidence increased 30% in women and 50% in men per each 10°increment of latitude. The explanations of this geographical variation have largely been considered to reflect changes in ambient ultraviolet radiation (UVR) and/ or concomitant variations in vitamin D sufficiency 5 although this is by no means the only potential explanation. 6 7 Using space-time cluster analysis, studies have demonstrated a high degree of clustering of residence was associated with a lower age at onset (AAO) of MS. 8 9 From these studies, it is reasonable to assume that there may exist an association between latitude and AAO for patients with MS. However, little data are available on whether a higher latitude or lower ambient UVR is associated with a lower AAO.
The latitudinal gradient has been shown to be present largely in populations of European descent 2 and also to vary by MS phenotype. 10 It is unclear whether the latitudinal gradient of MS also affects clinical characteristics, although some recent studies 11 12 have demonstrated a significant relationship between latitude and positivity for cerebrospinal fluid (CSF) oligoclonal bands (OCBs). A recent study in Japan has also confirmed this relationship between latitude and abnormal CSF findings, with a significant association of positive CSF findings (OR=4.08) and OCB positivity (OR=2.57) when comparing northern to southern Japan. 13 The association between AAO and the prognosis of patients with MS is complicated. A prospective population-based cohort study in southeast Wales 14 indicated that complete recovery from the onset event varied in different age groups, with full recovery more common (87.4%) in the youngest group (≤18 years), compared to only 68% in the oldest (≥44 years). Another cohort study also found that an older AAO could accelerate the accumulation of disability in MS, 15 and this association was independent of disease duration and early relapse frequencies. However, despite the fact that early onset patients with MS manifest a comparatively moderate clinical course, the younger onset was associated with a younger attainment of disability milestones. 16 While these studies have been consistent in their determination that AAO is a determinant of the progression of MS, less is known about the factors that influence the age of symptom onset in MS, with studies focusing on genetic, viral, metabolic and hormonal factors showing variable results. [17] [18] [19] In the present study, we sought to evaluate whether there was any evidence of a latitudinal variation in the age of symptom onset of MS and if so, whether such variation could be ascribed to a similar UV-based mechanism or if other factors were at play.
METHODS

The MSBase registry
The MSBase registry is an international collaboration that has established a prospective longitudinal data set of patients' with MS neurological records from a number of sites worldwide. Presently, the registry has 59 centres in 26 countries in Europe, North America, South America, Asia Minor, South Asia and Australia. Participating centres enter data in or near real time using a secure internet-based database.
Criteria for data extraction
All patients fulfilled either the 2005 or 2010 McDonald criteria 20 21 for diagnosis of MS, with the data being extracted and edited on 31 May 2014, a total of 30 415 participants were included (figure 1).
Participant inclusion criteria
Our data set was restricted to patients with clinically diagnosed MS as per the McDonald criteria 2010 20 and to adult-onset MS (excluding patients with AAO <16 years 22 23 ). The Atlas of MS 24 has demonstrated that the prevalence for MS between Asian and European populations varies significantly, from 1/100 000 to >180/100 000. In the present sample, other characteristics such as the populations mean age and the sex ratio of the source populations also differed significantly between sites. For example, sex ratio of source population (female/male) was 0.94 in non-European-descent centres (Isfahan, Iran; Kuwait City, Kuwait; Mumbai, India) while it was 1.06 in other centres, a significant difference ( p=2.74×10 −6 ). Likewise, the mean age of the source population differed significantly, with mean age of 33.39 years in non-European-descent centres compared to 39.33 years in European-descent centres ( p=8.34×10 −6 ). This marked variation in population characteristics and the heterogeneity of main effects between the two centre subsets led to our excluding these three centres from our analysis (figure 1). These exclusions left a total of 22 162 patients from 52 centres in 21 countries.
Factors of interest
Participant birthdate, sex, first recorded MS type (relapsing onset, progressive onset) and date of symptom onset, and current MS types, as well as the location of the registered MSBase centre (city, country) were recorded for every participant.
Age at onset AAO was defined as the age of the first validated symptom(s) consistent with MS.
Latitude
The latitude of each study centre was derived from Google maps (https://http://www.google.com.au/maps/). For our purposes, latitudes were recoded to all be positive, though we retained information on the hemisphere of the study centre to allow for evaluation of differences by hemisphere. For a better presentation of the latitudinal gradient and according to the sample distribution in our study, latitude was categorised into three strata: <40°, 40-50°and >50°. Using other cut points such as quartiles or 10°increments did not significantly alter the data.
Solar radiation values
We created a ultraviolet B (UVB) variable for each MSBase participant based on the latitude and longitude of each treatment centre. UVB (wavelengths 280-320 nm) was our focus in this study, since only shorter wavelength UVB radiation can induce the cutaneous synthesis of vitamin D. UV data were collected from the Solar Radiation Database service. Hourly values for clear sky were calculated and summed to daily or monthly values. UVB intensity was defined as radiation received per area, expressed as Wh/m 2 (watt hour per square metre). Mean monthly values from December to February were used to calculate the winter mean UVB for the northern hemisphere and from June to August for the southern hemisphere. Research 25 has demonstrated that UVR can modulate the immune response independent of the effect of vitamin D; however, all UV measurements are highly correlated for example, erythemally weighted UVR and UVB (r=0.99, p<0.001), therefore there was no difference in outcomes when using any measure of UVR.
Potential confounding variables Population mean age
It was reasonable to assume that a higher mean age in the source population could have an impact on the number of cases available for the study, given the average age of prevalent cases being in earlymid-adulthood. In terms of our data set, we found a positive association between population mean age and AAO (r=0.06, p<0.001) and latitude ( p=0.49, r<0.001), therefore population averaged age was included in the multivariable model. We obtained the mean age of the source population in each treatment centre from the most recent national demographic statistics available for each country.
Sex ratio in each treatment centre
Since female patients exhibit an earlier AAO, and there was a negative association between sex ratio (female/male) and latitude (r=−0.29, p<0.001), this was added to the multivariable model. From the sex distribution of patients with MS in each treatment centre we calculated the sex ratio (female/male).
MS type ratio in each treatment centre AAO in relapsing-onset patients is typically earlier than progressive-onset patients, and we found a positive association between the ratio of MS type ( progressive onset/relapsing onset) at each centre and latitude (r=0.38, p<0.001), therefore MS type ratio in each treatment centre was added to the multivariable model.
Statistical analysis
Linear regression was used to assess potential predictors of AAO. Since we excluded all patients <16 years, the distribution of AAO in our data set was left skewed. Log transformation was applied to reduce heteroskedasticity and thus satisfy the requirements of linear regression. All coefficients were back-transformed to present on the original scale at the mean of model covariates, however, to facilitate interpretation of results. Owing to the significant heterogeneity of the sample size in each treatment centre, all analyses were weighted by the square root of the sample size in each treatment centre.
To assess the seasonality of the AAO, we fitted a sinusoidal model to data on AAO and the month (t) when the patient was born: AAO=β 0 +β 1 sin(2πt/12)+β 2 cos(2πt/12). The analysis of variance F-test was used to decide whether there was significant seasonal variation.
All statistical analyses were undertaken using Stata/SE V.12.1 (College Park, Texas, USA).
RESULTS
Participant characteristics
Our analysis data set included a total of 22 162 patients from 52 centres in 21 countries (table 1). In keeping with known MS distributions most patients were women (70.4%) and of relapsing-remitting course (91.5%). The distribution of the cohort was such that most patients were from the northern hemisphere (81.4%), particularly Europe (67.2%), while participants from Australia also contributed a large proportion (15.7%). The mean AAO in this cohort was 32.3 years. Online supplemental table S1 shows the characteristics of the total cohort, overall and by centre.
Factors associated with AAO Latitude and UVB
Our primary factor of interest for AAO was the study centre latitude. In the univariable analysis, latitude as a continuous linear factor was significantly negatively associated with AAO ( p=0.01), every 10°increment of latitude associated with a 0.3-year earlier onset. Evaluating this as a categorical term in table 2, we found a clear dose-dependent response. On adjustment of relevant covariates, this association became much more dose dependent, with those of the highest latitude stratum having nearly 1.9 years earlier AAO than those of the lowest (figure 2). When we evaluated latitude as a continuous variable in the multivariable analysis, a 10°increase in latitude was associated with a 0.82-year earlier onset ( p=2.20×10 −13 ). We did not include UV in our multivariable analysis, due to the significant collinearity between the level of UV and latitude. In the online supplementary table S2, we show the stepwise process of the adjustment used in our multivariable model.
The results for the association between AAO and winter UVB were similar to the latitudinal ones, and the results were predictably of high correlation (r=−0.96, p<0.001) between latitude and UVB. In the univariable analysis, no strong dose-response relationship was observed, but the association and dose dependency were enhanced after adjustment for confounders. A clear dosedependent association (p=1.56×10 −17 ) appeared with those of the lowest UVB level having nearly 2 years earlier AAO than those of the highest UVB category in the multivariable analysis (figure 3). Using summer UVB and winter erythemally weighted UV, the positive relationship between higher sun exposure and later AAO persisted (p=5.85×10 −19 and p=7.59×10
−17
).
Sex
Female patients' AAO were on average 0.88 years (95% CI 0.60 to 1.17; p=1.28×10 −9 ) lower than male patients in our 
MS type
Progressive-onset patients exhibited a much later AAO than relapsing-onset patients with MS (β: 9.29; 95% CI 8.74 to 9.84; p=1.8×10 −293 ) ( 
Season of birth
Birth dates were relatively evenly distributed in all the four seasons. We explored season of birth (figure 4) and its association with AAO using a sinusoidal model, finding no seasonal pattern (F=0.66, p=0.52). 
DISCUSSION
Using one of the largest cohorts to date with 22 162 patients from 21 countries, we evaluated the role of latitude and age of MS symptom onset in adult, European-descent patients. We found evidence that those living at higher latitude had a significantly younger AAO, with every 10°increase in latitude associated with around a 10-month earlier AAO. The results were consistent when latitude was analysed as a categorical variable, demonstrating a strong inverse association between latitude and AAO, such that those in the highest latitudinal range had a nearly 2 years earlier onset than those in the lowest latitudinal range. Accordingly, we found a positive association between a lower winter ambient UV level and an earlier AAO, these results are neatly in harmony due to the known relationship between UV levels and latitude. Sex and MS type showed expected differences in AAO; however, we found no difference in AAO by season/month of birth.
In line with our results, one previous study 26 also found that latitude was negatively associated with AAO in patients with relapsing-remitting MS (RRMS), although this association was not significant ( p=0.10). However, the magnitude of the latitudinal association observed in that study (1.3 years change in per 10°latitude) is greater than the findings in our study, the absence of significance simply reflecting their smaller sample size of 987 patients. The difference in those findings and the present work likely reflects the difference in study samples (mostly Caucasian US military veterans vs a worldwide collaborative patient records database).
Variation of ambient winter UV is a possible but not the only explanation for this latitudinal variation in AAO, in line with previous research indicating associations between vitamin D/UV in MS onset and progression. 27 28 We used mean winter UV intensity in different centres as a predicted variable to analyse the association with AAO. Owing to the close relationship between latitude and UVB radiation (r=−0.96, p<0.001 in our study), we were unable to extract the individual effects to determine which was the more potent driver of effect. This likely reflects the less sensitive mode of assessing latitude or UV, by using surrogate latitude or ambient UV levels at the study centre rather than assessing individual participant exposure. However, the similarity of the two models also suggested that UVR is the main factor underlying the association of latitude and onset age.
A recent study in Japan demonstrated that latitude had a more significant impact on prevalence of MS than UVB, 29 and some studies have proposed that factors other than UVR may lead to the latitudinal gradient. 7 The latitudinal gradient of Epstein-Barr virus (EBV) infection prevalence may also partly explain the earlier onset at high latitudinal regions. A recent meta-analysis demonstrated that an increased rate of EBV infection in higher latitudinal areas occurred in both patients with MS and the general populations. 6 Another study 30 found a similar geographical distribution between infectious mononucleosis and MS that may also contribute to the latitudinal gradient in prevalence and also potentially AAO. However, an ecological study 31 performed in Australia showed a closer relationship between ambient UVR and MS prevalence (r=−0.91, p=0.01) when compared with the relationship of latitudes (r=0.89, p=0.02). Another study conducted by our group including 136 patients with MS found that increasing exposure to sun in adolescence was not associated with AAO. 32 However, this study found that skin phenotype was associated with AAO, which may be driven by the differential ability of skin types to absorb UV and synthesise vitamin D. A recent study 33 with a larger sample size (n=540) suggested that cumulative sun exposure (more than 16 weeks) in fall/winter in the 9-15 years age group was associated with 2.1 years later AAO ( p=0.02), persisting on adjustment for sunscreen use, cod liver oil intake, sex and skin type. Genetic variation is another potential factor that may account for the latitudinal gradient of AAO; our previous study 2 demonstrated enhancement of the association between latitude and prevalence of MS by genotype particularly HLA-DRB1. Another study 34 showed that HLA-DRB1 genotype could account for up to 52% of the latitudinal gradient of prevalence.
We also showed that women exhibit an earlier AAO than men and this relationship has been supported by many other studies. One study 14 with 1424 patients conducted in southeast Wales showed a significant difference of AAO between sexes (male 31.2, female 29.3, p=0.002). This difference is in the same direction as our results, but the magnitude was larger than ours. Likely the difference in magnitude reflects the different populations assessed. It may be that latitudinal or sex effects may be appreciably either greater or lesser in local regions, but in a multicentre databasebased study as ours, such regional differences may average out to yield a reduced magnitude of difference. Earlier puberty in females may be a candidate explanation for the earlier onset in females, as a study has found a positive association between age of menarche and AAO. 35 Progressive-onset patients showed onset ∼9 years later than relapsing-onset patients. Some research has also shown a positive relationship between additional year of AAO and the progressive-onset phenotype. 36 The study 36 within the Lyon MS Cohort showed a similar magnitude to our study with their mean AAO in primary-progressive MS (PPMS) and RRMS being 40.6-29.4 years, respectively.
Studies in a number of countries with a high prevalence of MS have demonstrated that more people with MS were born in spring and relatively few in autumn. 37 An international study 38 including 11 415 patients from 15 countries has shown that this seasonal association existed but did not correlate with variation in UVR exposure ( p=0.086). A multicentre longitudinal study 39 conducted in Australia also demonstrated a higher risk of MS for those born in November-December when compared to those born in May-June ( p<0.01). Our study showed that there was no clear association with month or season of birth and AAO. This is in keeping with the finding that the association between MS risk and month of birth was debatable when enough variables were included in the analysis 40 (especially those variables associated with regional and temporal variation). Figure 4 Mean age at symptom onset by month of birth. All southern hemisphere birth dates were moved 6 months forward to sync with northern hemisphere seasons.
We made the assumption that patients generally were born and lived in the same latitude where the study centres were located. This is not an unreasonable expectation; however, our inability to exclude patients who fell outside this assumption may affect our results. However, we believe that this misclassification error should be evenly distributed and would not impact the association of latitude and AAO.
Our analysis had remarkable statistical power provided by 22 162 patients from an international population-based cohort. Accordingly, while we have noted statistical significance, we were appropriately focused on magnitudes of difference in AAO. Our study does have some limitations, however. First, we had no individual information on diet, dietary supplementation ( particularly with vitamin D), and likewise individual genetic characteristics was not available. The lack of personal information leads to a lower explainable variance in our study. Second, a risk of selection bias might come from potentially uneven recruitment at some centres, but we weighted by the count of patients in each centre in our study, which decrease such intercentre variations. Additionally, our data are limited to those MS cases of European origin and adult onset and cannot be generalised to other non-European or paediatric onset cases.
In conclusion, this study confirms the presence of a significant inverse latitudinal gradient in the onset age in MS, such that each 10°increased latitude was associated with a 0.8 years earlier onset. Our results also support that variation of UVR exposure may play a role in the latitudinal gradient, although other factors such as differential timing of EBV infection and genetic background may also have a role. No difference in onset age by season or month of birth was seen, however, suggesting that while such in utero effects may modulate MS risk, the onset age may be determined by latitudinally varying exposures occurring after birth. The increased likelihood of patients living in higher latitude areas to suffer an earlier onset of MS may lead to improved understanding of MS aetiopathogenesis.
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